AC
CLDX icon

Apex Capital’s Celldex Therapeutics CLDX Stock Holding History

Apex Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-33,827
Closed -$8.28M – 58
2014
Q2 		$8.28M Sell
33,827
-506
-1% -$114K 0.52% 63
2014
Q1 		$9.1M Buy
+34,333
New +$13.1M 0.64% 50

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Apex Capital's CLDX Position: Q3 2014 in Review

Apex Capital sold out of Celldex Therapeutics (CLDX) in Q3 2014, closing a stake of 33,827 shares — an estimated $8.28M sold.

Apex Capital first reported a position in CLDX in Q1 2014 and held it in 2 quarters. The position peaked at $9.1M in Q1 2014. 148 funds tracked by Wall St. Rank hold CLDX as of Q3 2014.

  • Apex Capital reported no remaining Celldex Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Apex Capital sold 33,827 Celldex Therapeutics shares in Q3 2014, an estimated $8.28M.
  • Apex Capital first reported a position in Celldex Therapeutics in Q1 2014 and held it in 2 quarters.
  • Apex Capital's Celldex Therapeutics position peaked at $9.1M in Q1 2014.
  • 148 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2014.

Based on Apex Capital's 13F filing for Q3 2014, filed 4 Nov 2014.